Due to the sharp decline in sales of COVID-19 products of roughly CHF 5 billion, Roche expects a decrease in Group sales in the low single digit range. Excluding this COVID-19 sales decline, Roche anticipates solid sales growth in both divisions’ base business. Core earnings per share are targeted to develop broadly in line with the sales decline. Roche expects to further increase its dividend in Swiss francs.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
- Roche announces Vabysmo data suggests greater retinal drying vs. aflibercept
- New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME
- [Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma